Market cap
$1,225 Mln
Recently Viewed
Clear All$17.08
$-0.05
(-0.29%)
As on 22-Apr-2026 16:00EDT
Market cap
$1,225 Mln
Revenue (TTM)
$403 Mln
P/E Ratio
433.5
P/B Ratio
4.4
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
0 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
33.9
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
70,625,230
CFO
$264.39 Mln
EBITDA
$230.05 Mln
Net Profit
$-6.26 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Pharming Group N.V. ADS each representing 10 (PHAR)
| -3.3 | 11.2 | -4.7 | 109.6 | 16.9 | 4.7 | -- |
|
BSE Sensex*
| -8.3 | 4.2 | -5.6 | -2.4 | 9.2 | 10.1 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Pharming Group N.V. ADS each representing 10 (PHAR)
| 75.6 | -11.9 | 3.6 | 23.4 | -41.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Pharming Group N.V. ADS each representing 10 (PHAR)
|
17.1 | 1,224.6 | 403.3 | 22.8 | 3,081.6 | 9.1 | 433.5 | 4.4 |
| 2.3 | 5.3 | 5.8 | -3.4 | -40.8 | -44 | -- | 0.6 | |
| 0.4 | 15.9 | 0.0 | -9.7 | -5,195.6 | -- | -- | 227.7 | |
| 2.3 | 118.7 | 190.0 | -60.3 | -15.3 | -- | -- | 23.6 | |
| 0.1 | 2.1 | 0.0 | -2.6 | -17,715.7 | -- | -- | 38.3 |
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is... RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K" inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands. Read more
President, CEO & Executive Director
Dr. Sijmen de Vries M.B.A., M.D.
President, CEO & Executive Director
Dr. Sijmen de Vries M.B.A., M.D.
Headquarters
Leiden
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Pharming Group NV ADS each representing 10 (PHAR) is $17.08 (NASDAQ) as of 22-Apr-2026 16:00 EDT. Pharming Group NV ADS each representing 10 (PHAR) has given a return of 16.87% in the last 3 years.
The P/E ratio of Pharming Group NV ADS each representing 10 (PHAR) is 433.50 times as on 17-Apr-2026.
The P/B ratio of Pharming Group NV ADS each representing 10 (PHAR) is 4.43 times as on 17-Apr-2026, a 22 discount to its peers’ median range of 5.71 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
463.55
|
4.78
|
|
2024
|
-67.15
|
3.60
|
|
2023
|
-79.10
|
3.81
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
The 52-week high and low of Pharming Group NV ADS each representing 10 (PHAR) are Rs 21.34 and Rs 8.05 as of 23-Apr-2026.
Pharming Group NV ADS each representing 10 (PHAR) has a market capitalisation of $ 1,225 Mln as on 17-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Pharming Group NV ADS each representing 10 (PHAR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.